Mira Pharmaceuticals, Inc. 8-K Filing
Ticker: MIRA · Form: 8-K · Filed: Dec 22, 2025 · CIK: 1904286
| Field | Detail |
|---|---|
| Company | Mira Pharmaceuticals, Inc. (MIRA) |
| Form Type | 8-K |
| Filed Date | Dec 22, 2025 |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $242,258, $80,753, $915,000 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Mira Pharmaceuticals, Inc. (ticker: MIRA) to the SEC on Dec 22, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (nge on which registered Common Stock, $0.0001 par value per share MIRA The Nasdaq); $242,258 (proved a short-term incentive payout of $242,258. An additional payout of $80,753 remain); $80,753 (ut of $242,258. An additional payout of $80,753 remains contingent upon the completion); $915,000 (pproved a transaction advisory award of $915,000. This amount may be delivered in cash,).
How long is this filing?
Mira Pharmaceuticals, Inc.'s 8-K filing is 2 pages with approximately 641 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 641 words · 3 min read · ~2 pages · Grade level 14 · Accepted 2025-12-19 20:00:25
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share MIRA The Nasdaq
- $242,258 — proved a short-term incentive payout of $242,258. An additional payout of $80,753 remain
- $80,753 — ut of $242,258. An additional payout of $80,753 remains contingent upon the completion
- $915,000 — pproved a transaction advisory award of $915,000. This amount may be delivered in cash,
Filing Documents
- form8-k.htm (8-K) — 40KB
- 0001493152-25-028619.txt ( ) — 205KB
- mira-20251217.xsd (EX-101.SCH) — 3KB
- mira-20251217_lab.xml (EX-101.LAB) — 33KB
- mira-20251217_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MIRA PHARMACUTICALS, INC. Dated: December 19, 2025 By: /s/ Erez Aminov Name: Erez Aminov Title: Chief Executive Officer